

OncoOne Q2 2022 Newsletter


Message from the CEO, Dr. Randolph Kerschbaumer

With another successful quarter in the books at OncoOne, I value this opportunity to update you on OncoOne's progress over the last three months and discuss where we are headed in the second half of 2022. Our team presented key data sets at multiple important oncology and inflammation scientific meetings this quarter as our science was recognized as among the best at more than one conference! With our Series B raise underway and our two novel oxMIF monoclonal antibodies approaching the clinic in 2023, we welcome the opportunity to reconnect with you with this brief update. Enjoy!

Second Quarter 2022 Highlights

1. From the **BIO International Convention in San Diego** to the **Theranostics World Congress (TWC)**, and several scientific conferences in between, the OncoOne team has been on the road continuing our discussions with potential strategic partners and Series B investors. The OncoOne team has been excited to be back to face-to-face meetings with you all while showcasing our science.
2. The OncoOne team **presented preclinical data** surrounding ON203, our lead oxMIF asset for solid tumors, at **key industry conferences** including the **European Association for Cancer Research (EACR) Annual Congress** and the **European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO GI)**.

At **EACR**, Dr. Barbara Maurer (right) shared a poster of the preclinical data for ON203 demonstrating tumor stasis in a prophylactic mouse model and significant tumor reduction in a therapeutic setting. These models demonstrated significantly reduced tumor cell proliferation and intravasation pointing to ON203's potential to be effective as a single agent in solid tumors.



Dr. Maurer presents preclinical data on ON203 at the EACR

At **ESMO GI**, Barbara presented colorectal cancer human tumor organoid data which preserve an intact tumor microenvironment. ON203 demonstrated tumor cell killing in 4 out of 5 tumor isolates with one tumoroid demonstrating a 55% response over control. ON203 also effectively activated immune effector cells in the tumor microenvironment: M1 macrophages and natural killer (NK) cells were elevated in numbers and NK cells displayed increased activation and degranulation markers.

3. **Award season:** Our Director of Preclinical Development & Project Lead Inflammation, **Dr. Christine Landlinger**, won the oral communication award at the **World Congress on Inflammation** in Rome for her talk covering the preclinical data supporting our anti-oxMIF antibody, ON104.



Dr. Landlinger wins Award at WCI 2022

Our Director CMC Biologics, **Friedmund Bachmann** won an award for his **Theranostic World Congress poster**, “Novel diagnostic radioimmunoconjugate targeting oxMIF.” This poster detailing the potential to leverage an oxMIF antibody for diagnostic use was selected as one of top three abstracts at the conference.



4. We held a **successful pre-IND meeting with the FDA for ON203**, a therapeutic monoclonal antibody targeting oxMIF for the treatment of solid tumors. This is a critical milestone as we get closer to **entering the clinic** with our lead candidate.

Upcoming Events

Meet OncoOne company representatives at the following upcoming events in the 3rd Quarter:

- 2022 World Conference on Lung Cancer; August 6–9, Vienna, Austria (Poster presentation by Christine Landlinger)
- 2022 BIO Asia-Taiwan; July 27-31 (Brent Meadows will be available for 1:1 meetings)
- ESMO Congress 2022; September 9-13, Paris
- World Multispecific Summit, September 20-22, Boston, MA (Alexander Schinagl will give an oral presentation)

Get the latest updates: follow @OncoOne on [LinkedIn](#) and [Twitter](#).

OncoOne’s founders **discovered** and **named** the **oxidized isoform of MIF** and have developed optimized monoclonal antibody-based therapies to **treat a range of solid tumors and inflammation** as both single-agents or in combination with standard of care regimens.

Utilizing their foundational knowledge of oxMIF and expertise in drug development, OncoOne presents a **unique opportunity in overcoming the challenges of drugging the critical cytokine MIF** and thereby **accessing major markets** with their ability to harness the therapeutic effects of this novel target.

OncoOne is currently holding discussions for an **upcoming Series B** financing round which will advance ON203 through to phase II proof of concept and accelerate ON104 into clinic in 2023. We are also engaged in potential partnering opportunities based on our pipeline and expertise including securing a strategic partner for development and commercialization in the Asia-Pacific market.

Contact us: email Brent Meadows, CBO of OncoOne at brent.meadows@oncoone.com